This study demonstrated the use of Biopico's OrganRX™ multiorgan platform to model Alzheimer's disease-related cellular senescence in a physiologically connected human tissue system consisting of brain, liver, kidney, and gut tissues. The goal was to evaluate whether anti-senescence therapies could reduce amyloid-beta (Aβ)-induced cellular aging, a key feature associated with Alzheimer's disease.

To induce senescence, neuronal cultures were exposed to amyloid-beta (Aβ). Senescence was quantified using SA-β-galactosidase staining, RTPCR genes PAI-1 and p21 and Reactive Oxygen Species, common markers of cellular aging. The investigators then evaluated the ability of Tacrine and the senolytic combination Dasatinib + Quercetin (D+Q) to prevent or reduce senescence.